

Multimmune GmbH and Boulder Diagnostics Inc announce the development of an HSP70 lateral flow point of care test

Munich, Germany and Boulder Colorado, January 13th - Multimmune GmbH and Boulder Diagnostics Inc. announce today the joint development of an HSP70 lateral flow point of care test. Multimmune has discovered that many tumor types display the heat shock protein 70 (Hsp70) on the cell surface. Multimmune is exploiting this signal for directed immune therapy to cure cancers. The HSP70 lateral flow point of care test is being developed to test for elevated HSP70 levels in the blood of cancer patients and to evaluate the correlation of this occurrence with the presence of the tumor specific HSP70 cell surface marker. Boulder Diagnostics Inc. draws on its leading competence in lateral flow assay development to develop the HSP70 point of care test.

"The HSP70 point of care test will help us more rapidly to advance the important concept of tumor therapy against HSP70 expressing cancers", comments Claus Botzler, Managing Director of Multimmune GmbH.

"We are excited to apply our extensive lateral flow assay development expertise to this novel and important diagnostic opportunity", states Dede Willis, Chief Operating Officer of Boulder Diagnostics Inc.

About Multimmune:

Multimmune develops tumor therapies based on exploitation of tumorspecific cell surface markers. Multimmune has advanced an ex vivo immune recruitment therapy against HSP70 displaying colon and lung cancers through clinical phase I and has demonstrated pre-clinical proof of concept of an antibody therapeutic against HSP70 displaying tumors.

About Boulder Diagnostics:

Boulder Diagnostics is dedicated to the development of point of care lateral flow diagnostic assays and is currently developing products to detect elevated homocysteine levels and for the diagnosis of Lyme disease.

Contact

For Multimmune GmbH:

Dr. Claus Botzler

Managing Director

Phone: +49-170-4829150

Email: claus.botzler@multimmune.de

Web: www.multimmune.de

For Boulder Diagnostics Inc:

Dede Willis

Chief Operating Officer

Phone: +1-720-897-6276

Email: dwillis@boulderdiagnostics.com

Web: www.boulderdiagnostics.com